Cargando…
Targeting cancers in the gastrointestinal tract: role of capecitabine
Capecitabine is currently the only novel, orally home-administered fluorouracil prodrug. It offers patients more freedom from hospital visits and less inconvenience and complications associated with infusion devices. The drug has been extensively studied in large clinical trials in many solid tumors...
Autor principal: | Saif, Muhammad Wasif |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2886333/ https://www.ncbi.nlm.nih.gov/pubmed/20616892 |
Ejemplares similares
-
Current use and potential role of bevacizumab in the treatment of gastrointestinal cancers
por: Li, Jia, et al.
Publicado: (2009) -
Profile of capecitabine/temozolomide combination in the treatment of well-differentiated neuroendocrine tumors
por: Kotteas, Elias A, et al.
Publicado: (2016) -
Hypokalemia secondary to capecitabine: a hidden toxicity?
por: Saif, Muhammad Wasif, et al.
Publicado: (2007) -
Racial and ethnic differences in capecitabine toxicity in patients with gastrointestinal tract cancers
por: Brazelton, Alicia, et al.
Publicado: (2022) -
2016 Gastrointestinal Cancers Symposium: update on pancreatic cancer
por: Russo, Suzanne, et al.
Publicado: (2016)